Squamous cell lung cancer: From tumor genomics to cancer therapeutics

David R Gandara, Peter S. Hammerman, Martin L. Sos, Primo N Lara, Fred R. Hirsch

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged behind the now more common non-small cell lung cancer histologic subtype of adenocarcinoma. However, recent efforts to define the complex biology underlying SCC have begun to bear fruit in a multitude of ways, including characterization of previously unknown genomic and signaling pathways, delineation of new, potentially actionable molecular targets, and subsequent development of a large number of agents directed against unique SCC-associated molecular abnormalities. For the first time, SCC-specific prognostic gene signatures and predictive biomarkers of new therapeutic agents are emerging. In addition, recent and ongoing clinical trials, including the Lung-MAP master protocol, have been designed to facilitate approval of targeted therapy-biomarker combinations. In this comprehensive review, we describe the current status of SCC therapeutics, recent advances in the understanding of SCC biology and prognostic gene signatures, and the development of innovative new clinical trials, all of which offer new hope for patients with advanced SCC.

Original languageEnglish (US)
Pages (from-to)2236-2243
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number10
DOIs
StatePublished - May 15 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Squamous cell lung cancer: From tumor genomics to cancer therapeutics'. Together they form a unique fingerprint.

  • Cite this